JP2004529963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529963A5 JP2004529963A5 JP2002591041A JP2002591041A JP2004529963A5 JP 2004529963 A5 JP2004529963 A5 JP 2004529963A5 JP 2002591041 A JP2002591041 A JP 2002591041A JP 2002591041 A JP2002591041 A JP 2002591041A JP 2004529963 A5 JP2004529963 A5 JP 2004529963A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- antibody molecule
- conjugate
- maytansinoid
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical group 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 108010058905 CD44v6 antigen Proteins 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000005647 linker group Chemical group 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 102000048851 human CD44 Human genes 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112227A EP1258255A1 (en) | 2001-05-18 | 2001-05-18 | Conjugates of an antibody to CD44 and a maytansinoid |
| PCT/EP2002/005413 WO2002094325A2 (en) | 2001-05-18 | 2002-05-16 | Cytotoxic cd44 antibody immunoconjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529963A JP2004529963A (ja) | 2004-09-30 |
| JP2004529963A5 true JP2004529963A5 (https=) | 2006-01-05 |
Family
ID=8177473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002591041A Pending JP2004529963A (ja) | 2001-05-18 | 2002-05-16 | 細胞傷害性ｃｄ４４抗体免疫コンジュゲート |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP1258255A1 (https=) |
| JP (1) | JP2004529963A (https=) |
| KR (1) | KR20030097883A (https=) |
| CN (1) | CN1509187A (https=) |
| AR (1) | AR035977A1 (https=) |
| BG (1) | BG108366A (https=) |
| BR (1) | BR0209862A (https=) |
| CA (1) | CA2443438A1 (https=) |
| CO (1) | CO5550468A2 (https=) |
| CZ (1) | CZ20033477A3 (https=) |
| EA (1) | EA200301159A1 (https=) |
| EE (1) | EE200300568A (https=) |
| HR (1) | HRP20030932A2 (https=) |
| HU (1) | HUP0400046A3 (https=) |
| IL (1) | IL157965A0 (https=) |
| MX (1) | MXPA03010432A (https=) |
| NO (1) | NO20035108L (https=) |
| NZ (1) | NZ530167A (https=) |
| PE (1) | PE20021097A1 (https=) |
| PL (1) | PL365480A1 (https=) |
| SK (1) | SK15582003A3 (https=) |
| WO (1) | WO2002094325A2 (https=) |
| YU (1) | YU91503A (https=) |
| ZA (1) | ZA200307364B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1417974A1 (en) * | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy |
| US7384744B2 (en) | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| DE10256083A1 (de) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| MXPA05011811A (es) * | 2003-05-20 | 2006-02-17 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinoides. |
| ATE496944T1 (de) * | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
| EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| US8603483B2 (en) | 2004-12-09 | 2013-12-10 | Janssen Biotech, Inc. | Anti-integrin immunoconjugates, methods and uses |
| ES2503719T3 (es) * | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN101374545B (zh) * | 2005-04-15 | 2012-03-28 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| AR059900A1 (es) * | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| TW201117814A (en) * | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| ME03353B (me) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
| GB201220901D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating pancreatic cancer |
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| GB201220889D0 (en) | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating metastasizing cancers |
| GB201220891D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived peptides for treating breast cancers |
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| BR112016004023A2 (pt) | 2013-08-26 | 2022-11-16 | Regeneron Pharma | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| WO2016150521A1 (en) * | 2015-03-26 | 2016-09-29 | Fundación Imdea Nanociencia | Functionalised magnetic nanoparticle |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| US12098215B2 (en) | 2016-06-06 | 2024-09-24 | Northwestern University | Fusion protein construct |
| EP3755717A4 (en) * | 2018-02-22 | 2022-01-26 | Multitude Inc. | THERAPEUTIC ANTIBODY AND USES THEREOF |
| CN114057874B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
| DE19648209A1 (de) * | 1996-11-21 | 1998-05-28 | Boehringer Ingelheim Int | Verfahren zur Tumorzelldepletion CD34-positiver Zellen |
| DE19708713C2 (de) * | 1997-03-04 | 2002-11-28 | Boehringer Ingelheim Int | Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen |
| BR0012196A (pt) * | 1999-06-25 | 2002-03-19 | Genentech Inc | Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado |
| AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
-
2001
- 2001-05-18 EP EP01112227A patent/EP1258255A1/en not_active Withdrawn
-
2002
- 2002-05-16 EA EA200301159A patent/EA200301159A1/ru unknown
- 2002-05-16 HU HU0400046A patent/HUP0400046A3/hu unknown
- 2002-05-16 MX MXPA03010432A patent/MXPA03010432A/es not_active Application Discontinuation
- 2002-05-16 PL PL02365480A patent/PL365480A1/xx not_active Application Discontinuation
- 2002-05-16 KR KR10-2003-7015037A patent/KR20030097883A/ko not_active Withdrawn
- 2002-05-16 CZ CZ20033477A patent/CZ20033477A3/cs unknown
- 2002-05-16 WO PCT/EP2002/005413 patent/WO2002094325A2/en not_active Ceased
- 2002-05-16 NZ NZ530167A patent/NZ530167A/en unknown
- 2002-05-16 EE EEP200300568A patent/EE200300568A/xx unknown
- 2002-05-16 EP EP02753054A patent/EP1395290A2/en not_active Withdrawn
- 2002-05-16 CA CA002443438A patent/CA2443438A1/en not_active Abandoned
- 2002-05-16 JP JP2002591041A patent/JP2004529963A/ja active Pending
- 2002-05-16 YU YU91503A patent/YU91503A/sh unknown
- 2002-05-16 BR BR0209862-8A patent/BR0209862A/pt not_active IP Right Cessation
- 2002-05-16 IL IL15796502A patent/IL157965A0/xx unknown
- 2002-05-16 CN CNA028101634A patent/CN1509187A/zh active Pending
- 2002-05-16 SK SK1558-2003A patent/SK15582003A3/sk not_active Application Discontinuation
- 2002-05-16 HR HR20030932A patent/HRP20030932A2/xx not_active Application Discontinuation
- 2002-05-17 PE PE2002000420A patent/PE20021097A1/es not_active Application Discontinuation
- 2002-05-17 AR ARP020101829A patent/AR035977A1/es not_active Application Discontinuation
-
2003
- 2003-09-22 ZA ZA200307364A patent/ZA200307364B/en unknown
- 2003-11-17 NO NO20035108A patent/NO20035108L/no not_active Application Discontinuation
- 2003-11-17 BG BG108366A patent/BG108366A/bg unknown
- 2003-11-18 CO CO03101695A patent/CO5550468A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529963A5 (https=) | ||
| JP7728821B2 (ja) | 抗体－薬物コンジュゲートの改良製造方法 | |
| US20220226497A1 (en) | Novel method for producing antibody-drug conjugate | |
| JP7362714B2 (ja) | アマニチンコンジュゲート | |
| ES2905842T3 (es) | Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor tipo Toll 7 (TLR7) como inmunoestimulantes | |
| ES2908984T3 (es) | Derivados de 6-amino-7,9-dihidro-8H-purin-8-ona como agonistas inmonoestimulantes del receptor tipo toll 7 (TLR7) | |
| ES2895369T3 (es) | Agonistas del receptor tipo toll 7 (TLR7) que tienen un resto tricíclico, conjugados de estos y métodos y usos de estos | |
| ES2904684T3 (es) | Derivados de 6-amino-7,9-dihidro-8H-purin-8-ona como agonistas del receptor tipo toll 7 (TLR7) inmunoestimulantes | |
| WO2023131219A1 (en) | Conjugates, compositions and methods of use | |
| JP5116686B2 (ja) | Ｃｃ−１０６５類似体の調製方法及び調製用化合物 | |
| EA027925B1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
| JP6957629B2 (ja) | 非線状自壊性リンカーおよびそのコンジュゲート | |
| TW202302643A (zh) | 抗ｈｅｒ２抗體－藥物結合物及其用途 | |
| JP7846634B2 (ja) | 抗体－免疫賦活化剤コンジュゲートの新規製造方法 | |
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| KR20250049293A (ko) | 항체-약물 접합체 및 이의 용도 | |
| CA3113378C (en) | Sulfomaleimide-based linkers and corresponding conjugates | |
| CN117069793A (zh) | 双功能接头化合物、抗体药物偶联物及其制备方法和应用 | |
| WO2018035391A1 (en) | Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use | |
| JP2026508115A (ja) | リンカー薬物、その抗体－薬物コンジュゲート、並びにそれらの調製方法及び使用 | |
| CA3236102A1 (en) | Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof | |
| TWI915810B (zh) | 抗體-藥物結合物之改良製造方法 | |
| CA3038427C (en) | Non-linear self-immolative linkers and conjugates thereof | |
| TW202613076A (zh) | 鏈接子－有效負載、由其作成之抗體－藥物共軛物及其用途 | |
| KR20230127918A (ko) | 신규 항체 약물 접합체 |